Press releasePRNewswire
Atossa Therapeutics
ATOS · NASDAQ
$2.54−$0.02 (−0.78%)TodayMarket closed ·
Prev close $2.56
Latest news
- Press releasePRNewswire
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
- Press releasePRNewswire
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
- Press releasePRNewswire
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
- Press releasePRNewswire
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
- Press releasePRNewswire
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
- Press releasePRNewswire
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
- Press releasePRNewswire
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings
- NewsAvi Kapoor
Dow Jumps Over 250 Points; US Initial Jobless Claims Rise
- Press releasePRNewswire
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
- Press releasePRNewswire
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
- Press releasePRNewswire
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
- Press releasePRNewswire
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
- Press releasePRNewswire
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
- Press releasePRNewswire
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
- Press releasePRNewswire
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
- Press releaseGlobe Newswire
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
- Press releasePRNewswire
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
- Press releasePRNewswire
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releasePRNewswire
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
- Press releasePRNewswire
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
- Press releasePRNewswire
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
- Press releasePRNewswire
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
- Press releasePRNewswire
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
- Press releasePRNewswire
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
- Press releasePRNewswire
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
- News
Earnings Scheduled For March 25, 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.